Cowen & Co. Thinks Agios Pharma’s Stock is Going to Recover

By Jason Carr

Cowen & Co. analyst Chris Shibutani reiterated a Buy rating on Agios Pharma (AGIOResearch Report) yesterday. The company’s shares closed yesterday at $47.35, close to its 52-week low of $41.63.

According to, Shibutani is a 3-star analyst with an average return of 1.1% and a 42.3% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Agios Pharma with a $85 average price target, representing a 79.5% upside. In a report issued on May 3, Piper Jaffray also maintained a Buy rating on the stock with a $85 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $99.82 and a one-year low of $41.63. Currently, Agios Pharma has an average volume of 488.7K.

Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.